Evidence map›Paper›PMID 35896714›Full record

ArticleScientific reports2022

Characterization of binding interactions of SARS-CoV-2 spike protein and DNA-peptide nanostructures.

Marlen Kruse, Basma Altattan, Eva-Maria Laux, Nico Grasse, Lars Heinig, Christin Möser, David M Smith, Ralph Hölzel

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Peptide foldamer-based inhibitors of the SARS-CoV-2 S protein-human ACE2 interaction.Journal of enzyme inhibition and medicinal chemistry · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marlen KruseFraunhofer IZI-BB, Am Mühlenberg 13, 14476, Potsdam, Germany. marlen.kruse@izi-bb.fraunhofer.de.
Basma AltattanFraunhofer IZI, Perlickstraße 1, 04103, Leipzig, Germany.
Eva-Maria LauxFraunhofer IZI-BB, Am Mühlenberg 13, 14476, Potsdam, Germany.
Nico GrasseFraunhofer IZI, Perlickstraße 1, 04103, Leipzig, Germany.
Lars HeinigPreclinics GmbH, Wetzlarer Straße 20, 14482, Potsdam, Germany.
Christin MöserFraunhofer IZI, Perlickstraße 1, 04103, Leipzig, Germany.
David M SmithFraunhofer IZI, Perlickstraße 1, 04103, Leipzig, Germany.
Ralph HölzelFraunhofer IZI-BB, Am Mühlenberg 13, 14476, Potsdam, Germany.
Fraunhofer Institute for Cell Therapy and Immunology · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Binding interactions of the spike proteins of the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) to a peptide fragment derived from the human angiotensin converting enzyme 2 (hACE2) receptor are investigated. The peptide is employed as capture moiety in enzyme linked immunosorbent assays (ELISA) and quantitative binding interaction measurements that are based on fluorescence proximity sensing (switchSENSE). In both techniques, the peptide is presented on an oligovalent DNA nanostructure, in order to assess the impact of mono- versus trivalent binding modes. As the analyte, the spike protein and several of its subunits are tested as well as inactivated SARS-CoV-2 and pseudo viruses. While binding of the peptide to the full-length spike protein can be observed, the subunits RBD and S1 do not exhibit binding in the employed concentrations. Variations of the amino acid sequence of the recombinant full-length spike proteins furthermore influence binding behavior. The peptide was coupled to DNA nanostructures that form a geometric complement to the trimeric structure of the spike protein binding sites. An increase in binding strength for trimeric peptide presentation compared to single peptide presentation could be generally observed in ELISA and was quantified in switchSENSE measurements. Binding to inactivated wild type viruses could be shown as well as qualitatively different binding behavior of the Alpha and Beta variants compared to the wild type virus strain in pseudo virus models.

Indexed as

COVID-19NanostructuresSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2DNAHumansPeptidesProtein BindingSARS-CoV-2ACE2 protein, humanAngiotensin-Converting Enzyme 2DNAPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID35896714
PMCPMC9328006
OpenAlexW4288068131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.